Delving into the Latest Updates on Medibiofarma SL with Synapse

A Phase IIa, Open Label, Single Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Dosed MBF-015 in Huntington's Disease Patients

This is a Phase IIa (proof of concept), single center clinical trial to evaluate the safety and efficacy of daily MBF-015 oral treatment during 28 days in Huntington's Disease patients on top of standard of care.

开始日期2024-02-01

申办/合作机构

Medibiofarma SL

CTIS2023-505241-10-00 / Recruiting

A phase IIa, open label, single centre study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally dosed MBF-015 in Huntington's disease patients - MBF-015CT-02

开始日期2024-02-01

申办/合作机构

Medibiofarma SL

NCT05940558 / Completed临床2期

A Phase IIa, Open Label, Single-centre Study to Assess the Initial Antifibrotic Efficacy, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of MBF-118 in Crohn's Disease Patients with Stenosis

This is a Phase IIa (proof of concept), single center clinical trial to evaluate the safety and efficacy of daily MBF-118 oral treatment during 28 days in Crohn's disease patients on top of standard of care.

开始日期2023-04-12

申办/合作机构

Medibiofarma SL

100 项与 Medibiofarma SL 相关的临床结果

登录后查看更多信息

0 项与 Medibiofarma SL 相关的专利（医药）

登录后查看更多信息

100 项与 Medibiofarma SL 相关的药物交易

登录后查看更多信息

100 项与 Medibiofarma SL 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月18日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

1

临床1期

临床2期

2

1

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

MBF-118 ( PPARγ )	克罗恩病更多	临床2期
MBF-015 ( HDAC1 x HDAC2 )	亨廷顿舞蹈病更多	临床2期
MBF-362 ( EP4 )	实体瘤更多	临床1期
MBF-132	肿瘤更多	药物发现
MBF-251 ( EP2 x EP4 )	肿瘤更多	终止